Nandrolone Decanoate — Competitive Intelligence Brief

Nandrolone Decanoate (NANDROLONE DECANOATE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen. Area: Hematology.

marketed Androgen Sex hormone-binding globulin Hematology Small molecule

Target snapshot

Nandrolone Decanoate (NANDROLONE DECANOATE) — Woodward Specl.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nandrolone Decanoate TARGET	NANDROLONE DECANOATE	Woodward Specl	marketed	Androgen	Sex hormone-binding globulin	1962-01-01
Nexplanon	ETONOGESTREL		marketed	Estrogen [EPC]	Sex hormone-binding globulin	2001-01-01
Ortho-Cept	DESOGESTREL	Merck & Co.	marketed	Progestin	Sex hormone-binding globulin	1992-01-01
Danzol	DANAZOL		marketed	Androgen [EPC]	Sex hormone-binding globulin	1976-01-01
Intrarosa	PRASTERONE		marketed	Non-Standardized Food Allergenic Extract [EPC]	Sex hormone-binding globulin
Nandrolon	NANDROLONE		marketed	Androgen	Sex hormone-binding globulin
Benzofoline	ESTRADIOL BENZOATE		marketed	Estrogen	Adenosine receptor A3, Sex hormone-binding globulin, 5-hydroxytryptamine receptor 2B

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen class)

1. · 4 drugs in this class
2. Azurity · 1 drug in this class
3. Endo · 1 drug in this class
4. Marius · 1 drug in this class
5. Merck & Co. · 1 drug in this class
6. The Affiliated Hospital of Qingdao University · 1 drug in this class
7. Woodward Specl · 1 drug in this class